Clinical Trial Update: COX-2 Inhibitor to Prevent Post-ERCP Pancreatitis [Phase 4]

View source ↗

Summary

This document provides an update on a Phase 4 trial investigating a COX-2 inhibitor to prevent acute pancreatitis after ERCP.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatitis

Drugs mentioned

• COX-2 inhibitor (COX-2 inhibitor)

Snippet

Sponsor: First Affiliated Hospital Xi'an Jiaotong University | Conditions: Pancreatitis, Acute | Phase 4 | Status: UNKNOWN